Telehealth Firms Urge FDA to Legalize Peptides With Oversight
Legal·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Telehealth companies including Hims & Hers and Noom have called on a panel of experts to recommend the legalization of several popular peptides. They emphasized the need for increased oversight and the establishment of a system to report side effects.
The push for legalization comes as these firms seek to expand their offerings while ensuring consumer safety. The companies believe that with proper guardrails in place, the benefits of these peptides can be safely harnessed.
Hims & HersNoomFDA
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Telehealth companies including Hims & Hers Health Inc. and Noom Inc. urged a panel of experts to recommend legalizing a handful of popular peptides, while calling for more oversight and the creation of a system to report side effects.”
Bloomberg — Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails